Pfizerin rokote 88% tehokas Intian varianttia vastaan

The COVID-19 vaccines developed by Pfizer/BioNTech and AstraZeneca/Oxford University are "highly effective" against the Indian variant, a new study has found.

Public Health England (PHE) said on Sunday that the Pfizer vaccine was 88 per cent effective against symptomatic disease from the Indian variant — named B.1.617.2 — two weeks after the second dose.

The AstraZeneca jab had an efficacy rate of 60 per cent.